Navigation Links
Phase I Safety and Tolerability Study With EVT 302 Successfully Completed
Date:1/7/2008

HAMBURG, Germany and OXFORD, England, January 7 /PRNewswire-FirstCall/ -- Evotec AG (Frankfurt Stock Exchange: EVT) today announced that it has successfully completed a Phase I safety and tolerability study with EVT 302. The preliminary results confirm the good tolerability profile of EVT 302 and are an encouraging basis for further clinical development.

EVT 302, a reversible and highly selective inhibitor of MAO-B in development for smoking cessation, was investigated in an ascending dose study with repeated daily dosing in a total of 84 healthy young and elderly subjects. Healthy young male subjects were treated with EVT 302 2.5, 5, 15 mg, or placebo for two weeks, and healthy elderly male and female subjects were treated with EVT 302 2.5 mg, 10 mg, or placebo for four weeks. Each treatment was received by 12 young and/or elderly subjects as appropriate. The highest dose levels exceed the expected maximum therapeutic dose planned to be used in further clinical trials. For the treatment period and part of the subsequent washout phase the subjects were confined to the clinical research unit.

The study was aimed at investigating safety/tolerability, pharmacokinetics, and pharmacodynamics (inhibition of MAO-B in platelets) during prolonged dosing with EVT 302 as compared to placebo. The study was conducted and successfully completed as planned per protocol. The results are still blinded and will become available as final evaluated data over the next two months.

The preliminary data indicate that EVT 302 was well tolerated in young and elderly subjects up to the highest dose levels tested in this study. Adverse events (AEs) classified as possibly treatment related were transient and mostly of mild intensity; only very few moderate AEs were reported. No severe or serious AEs occurred.

No clinically relevant changes in lab values of haematology or clinical chemistry were noted. In particular, there were no changes in liver function test
'/>"/>

SOURCE Evotec AG
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
2. Oncolytics Biotech Inc. Announces Filing of Phase 1/2 Clinical Trial with REOLYSIN(R)
3. Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
4. Oncolytics Biotech Inc. Completes Patient Enrolment in U.K. Phase Ia/Ib Combination REOLYSIN(R)/Radiation Clinical Trial
5. Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia
6. Genmab A/S - R1507 Antibody to Enter Phase II Study to Treat Sarcoma
7. ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimers Disease
8. Conatus Pharmaceuticals Initiates a Phase 2 Clinical Trial for the Treatment of Hepatitis
9. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
10. Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy
11. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)... at Economic Club of Canada , ...Ambassador to Speak at Economic Club of Canada., ,...ternational Investment, and Chairman and CEO of th...David Appia go to www.investinfrance.org . , , ,...press to discuss recent pro-business initiatives a...
(Date:11/25/2009)...--ArdeaBiosciences,Inc.(Nasdaq: RDEA )announcedtod...tiveofficer,willpresentatthePiperJaffray21stAnnual...follows:,PiperJaffray21stAnnualHealthCareConferen...nTime,Location:TheNewYorkPalaceHotel,NewYork,NY,We...target=,_blank,title=,http://www.corporate-ir.net/...
(Date:11/24/2009)...TwomoreprestigiousuniversitieshavejoinedBioCareerC...teforlifescienceprofessionals. ,, Northwesterna...ning28othermajorlifesciencetrainingInstitutions. ,...orpost-graduatesinthelifesciences.Whiletherearehun...erCenteristheonlyonethatserveslifesciencepost-grad...
(Date:11/24/2009)...re-FirstCall/--deCODE,genetics,Inc.(Nasdaq: DCGN )...onsbytheU.S.BankruptcyCourtfortheDistrictofDelawar...tarypetitionfor,reliefunderChapter11oftheUnitedSta...heordersissuedbytheBankruptcyCourtallowthecompanyt...oceedings.Inparticular,the,companyreceivedinterimB...
Breaking Biology Technology:French Ambassador for International Investment to Visit Toronto December 11 2Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference 2Two Major Universities Join Nation's Leading Postgrad Bio Job Board 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3
...ovides laboratory-quality results in physician,s o...olly-owned subsidiary of Quest Diagnostics Incorpo...ty of the InSure(R) Quik F I T(TM) fecal,immunoche...,s lab-based,InSure(R) FIT(TM) test, that provides...f the laboratory-based InSure FIT test., The avai...
...odality highlights Volcano commitment to intravasc...d research applications, SAN DIEGO and BRUSSELS, ... ), a leading manufacturer and developer of,intrav...(FM) and Optical,Coherence Tomography (OCT) produc... of coronary and peripheral vascular disease, anno...
...N.J., May 8 When pharmaceutical and,biotech chemi...J in,September to meet at the Pharma ChemOutsourci...st will be starting materials and Active,Pharmaceu...r on Asian,suppliers, rising prices and delivery t...ced in China to tighten quality control and protec...
Other Biology Technology:Enterix Inc. Launches Its Point-of-Care Test for Colorectal Cancer Screening 2Enterix Inc. Launches Its Point-of-Care Test for Colorectal Cancer Screening 3Enterix Inc. Launches Its Point-of-Care Test for Colorectal Cancer Screening 4Enterix Inc. Launches Its Point-of-Care Test for Colorectal Cancer Screening 5Volcano Corp Announces First Human Use of the Volcano Optical Coherence Tomography (OCT) Imaging Catheter 2Volcano Corp Announces First Human Use of the Volcano Optical Coherence Tomography (OCT) Imaging Catheter 3Volcano Corp Announces First Human Use of the Volcano Optical Coherence Tomography (OCT) Imaging Catheter 4API and Raw Material Supply Concerns Focal Point of Pharma ChemOutsourcing Conference September 8-9 in New Jersey 2
(Date:11/25/2009)...ens, Ga. Bacteria don,t have easy lives. In addit...ugs, they have natural enemies called bacteriophag...very two days. , Still, bacteria and another cl...ered in extreme environments such as deep-sea volc...ecause they have a built-in defense system that he...
(Date:11/25/2009)...r. Sarit Larisch, Head of the Cell Death Research ... of Biology, has been awarded the prestigious John...ch exploring the cause of brain cell damage in Par... year to scientists in support of innovation and e...fficially conferred earlier this month at an event...
(Date:11/25/2009)...r the course of a lifetime, the heart pumps some 2...e order to do this, the muscle fibers of the heart...headed by Dr. Wolfgang Rottbauer, vice chair of th...ity Hospital (Chairman: Prof. Dr. H. A. Katus), ha... stability of the smallest muscular unit, the sarc...
Breaking Biology News(10 mins):Researchers discover biological basis of 'bacterial immune system' 2Researchers discover biological basis of 'bacterial immune system' 3Johnson & Johnson award goes to research of the cause of brain cell damage in Parkinson's 2New genetic cause of cardiac failure discovered 2Implantable Defibrillators May Not Help Women With Heart Failure 57116 1Implantable Defibrillators May Not Help Women With Heart Failure 57116 2Implantable Defibrillators May Not Help Women With Heart Failure 57116 3Cancer risk raised after northern Italian industrial accident 57112 1Cancer risk raised after northern Italian industrial accident 57112 2Pacific Shore Holdings Inc Begins Clinical Trial With Burner Balm 57110 1Pacific Shore Holdings Inc Begins Clinical Trial With Burner Balm 57110 2
...sually protects the body,s infection-fighting cell...t arteries and lead to heart disease, UT Southwest...olecule, called apoptosis inhibitor of macrophage ...circulate in the bloodstream and help the body fen...otected macrophages go on to encourage buildup of ...
...sed life detection system developed by Carnegie Me... in Chile,s Atacama Desert, according to results b...ence Conference March 14-18 in Houston. This marks... has been used to identify life in this harsh regi... could be deployed in future Mars missions. , "Our...
...liposomes ?cell-like "water balloons" composed of ... to natural cell membranes ?have revealed unexpect...hat may provide a paradigm-shifting change in scie...rating living systems. , Arizona State University ...that liposomes have a tendency to form tube-like e...
Other Biology News:Molecule that usually protects infection-fighting cells may cause plaque deposits inside arteries 2Robot-based system developed at Carnegie Mellon detects life in Chile's Atacama desert 2Robot-based system developed at Carnegie Mellon detects life in Chile's Atacama desert 3Robot-based system developed at Carnegie Mellon detects life in Chile's Atacama desert 4
...er System from IKA Works is the worlds first close... and more efficient way to disperse samples. The I...5 ml inside sealed tubes. Depending on their sampl...tube types. Each tube is hermetically sealed for m...
...r ambient HPLC. Contains connections and on-board ...l devices such as RI and/or UV detectors. Also con...terfacing to strip chart recorders. Includes an in...er. On-board analog-to-digital conversion with RS-...
CD25 MicroBeads, non-human primate from Miltenyi Biotec
...r enhanced translation of cloned sequences in vitr...ulocyte lysate. The maps for pCITE-2b(+) and pCITE...ing exceptions: pCITE-2b(+) is a 3793 bp plasmid; ...btract 7 bp from all sites beyond Msc I at 522. pC...
Biology Products: